Evidence map›Paper›PMID 39985133›Full record

ArticleCancer biology & medicine2025

Improved treatment of colorectal liver metastases by early response evaluation and regimen adjustment: a prospective study of clinical functional MR-based modeling.

Wenhua Li, Huan Zhang, Zhe Gong, Yue Li, Zhiyu Chen, Xiaodong Zhu, Mingzhu Huang, Zhe Zhang, Chenchen Wang, Lixin Qiu and 7 more

Abstract read
In one paragraph

Article in Cancer biology & medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Wenhua Li *Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Huan Zhang *Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Zhe Gong *Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan 250000, China.
Yue Li *Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Zhiyu ChenDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Xiaodong ZhuDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Mingzhu HuangDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Zhe ZhangDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Chenchen WangDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Lixin QiuDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Qirong GengDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Jinjia ChangDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Xiaoying ZhaoDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Xuedan ShengDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Wen ZhangDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.ORCID 0009-0006-1717-3540
Tong TongDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.ORCID 0000-0002-9180-8181
Weijian GuoDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.ORCID 0000-0002-6155-8345

Funding

Innovative Achievement Transformation of Shenkang Medical-Enterprise Integration SHDC2023CRD014National Natural Science Foundation of China 82202101National Natural Science Foundation of China 82271946
6 · The paper itself

Abstract

objectiveThe aim of the study was to evaluate the feasibility of functional MR in predicting the clinical response to chemotherapy in patients with colorectal liver metastases (CLM).

methodsA total of 196 eligible patients were enrolled in the study between August 2016 and January 2023. Functional MR was performed at baseline and after one cycle of chemotherapy. The diffusion kurtosis radiomic texture features were extracted and a signature model was built using the R package. The initial 100 cases were designated as the training set, the following 48 cases were designated as the validation set, and the final 48 cases were designated as the intervention validation set.

resultsGood performance for the response prediction (AUC = 0.818 in the training set and 0.755 in the validation set) was demonstrated. The objective response rates (ORRs) in the high-risk subgroup were significantly lower than the low-risk subgroup in the training and validation sets. Worse progression-free survival and overall survival rates were noted in the high-risk population. In the intervention set 22.9% (11/48) of the chemotherapy regimens for patients were changed in response to the model-predicted results and the ORR reached 77.1% (37/48), which was significantly higher than the training and validation sets [47.97% (71/148);

conclusionsA functional MR signature effectively predicted the chemotherapy response and long-term survival. The adjustment of the regimen guided by the model significantly improved the ORR.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsColorectal NeoplasmsLiver NeoplasmsMagnetic Resonance ImagingAdultAgedFemaleHumansMaleMiddle AgedProspective StudiesTreatment OutcomeColorectal cancerliver metastasesMRobjective response rate

Identifiers

PMID39985133
PMCPMC11899590

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.